These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30265346)

  • 1. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
    Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM
    J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of the third non-functional human pancreatic neuroendocrine tumor cell line.
    Lou X; Ye Z; Xu X; Jiang M; Lu R; Jing D; Zhang W; Gao H; Wang F; Zhang Y; Chen X; Qin Y; Zhuo Q; Yu X; Ji S
    Hum Cell; 2022 Jul; 35(4):1248-1261. PubMed ID: 35394261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
    Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
    Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; Venegas-Moreno E; L-López F; Fanciulli A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Dios E; Blanco-Acevedo C; Solivera J; Granata R; Kineman RD; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
    Neuroendocrinology; 2020; 110(11-12):1028-1041. PubMed ID: 31940630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
    Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
    Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
    Aristizabal Prada ET; Weis C; Orth M; Lauseker M; Spöttl G; Maurer J; Grabowski P; Grossman A; Auernhammer CJ; Nölting S
    Neuroendocrinology; 2018; 106(4):335-351. PubMed ID: 28968593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
    Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
    Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Modlin I
    Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
    Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
    Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo.
    Tian Y; Zhen L; Bai J; Mei Y; Li Z; Lin A; Li X
    Pancreas; 2017 Sep; 46(8):1076-1081. PubMed ID: 28787336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; L-López F; Ibáñez-Costa A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Blanco-Acevedo C; Dios E; Venegas-Moreno E; Solivera J; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3501-3513. PubMed ID: 30860580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
    Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
    Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
    Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
    AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.